Benchling for RNA Therapeutics R&D
Benchling
Oct 20, 2021
Abstract
Because RNA therapeutics can target conditions that small molecules and proteins cannot address, researchers are now on the verge of treating previously “undruggable” diseases. From the approval of the first antisense oligonucleotide, aptamer, and siRNA, to the now famous launch of mRNA-based COVID-19 vaccines, the pipeline of RNA therapies and vaccines has expanded dramatically. However, as RNA therapeutics have gained traction scientifically and clinically, the software tools to engineer them have been frustratingly limited. This application note discusses complexities in RNA therapeutics R&D as well as how Benchling can help overcome these hurdles.
Application File
Benchling for RNA Therapeutics R&D.pdf
Premier Sponsor
Latest Protocols
- Zebrafish Tumor Graft Transplantation to Grow Tumors In Vivo That Engraft Poorly as Single Cell Suspensions
- An Automated Low-Cost Swim Tunnel for Measuring Swimming Performance in Fish
- A Rabbit Femoral Condyle Defect Model for Assessment of Osteochondral Tissue Regeneration
- Cartilage Assessment Requires a Surface Characterization Protocol: Roughness, Friction, and Function
Comments
Be the first to comment.